Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash & Current Investments of $22.1 billion for Q1 2026, up 9.7% sequentially from $20.1 billion in Q4 2025, and down 43.14% YoY from $38.8 billion in Q1 2025.
Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Cash & Current Investments data on file, last reported at $22.1 billion in Q1 2026.
- Quarterly Cash & Current Investments fell 43.14% year-over-year to $22.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 billion (down 43.14% YoY) and the FY2025 annual result came in at $20.1 billion, down 18.02% from the prior year.
- Cash & Current Investments grew to $22.1 billion in Q1 2026 per JNJ's latest filing, from $20.1 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $38.8 billion in Q1 2025, with the low at $18.6 billion in Q3 2025.
- Average Cash & Current Investments over 5 years is $25.9 billion, with a median of $24.6 billion recorded in 2023.
- Year-over-year, Cash & Current Investments surged 47.92% in 2025 and sank 43.14% in 2026.
- Johnson & Johnson's Cash & Current Investments stood at $34.1 billion in 2022, then slumped by 32.72% to $22.9 billion in 2023, then grew by 6.96% to $24.5 billion in 2024, then slipped by 18.02% to $20.1 billion in 2025, then increased by 9.7% to $22.1 billion in 2026.
- Business Quant data shows JNJ's Cash & Current Investments at $22.1 billion in Q1 2026, $20.1 billion in Q4 2025, and $18.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.94 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 22.05 Bn |
| Dec 28, 2025 | 20.10 Bn |
| Sep 28, 2025 | 18.56 Bn |
| Jun 29, 2025 | 18.88 Bn |
| Mar 30, 2025 | 38.78 Bn |
| Dec 29, 2024 | 24.52 Bn |
| Sep 29, 2024 | 20.30 Bn |
| Jun 30, 2024 | 25.48 Bn |
| Mar 31, 2024 | 26.22 Bn |
| Dec 31, 2023 | 22.93 Bn |
| Oct 1, 2023 | 23.51 Bn |
| Jul 2, 2023 | 28.51 Bn |
| Apr 2, 2023 | 24.61 Bn |
| Jan 1, 2023 | 22.28 Bn |
| Oct 2, 2022 | 34.08 Bn |
| Jul 3, 2022 | 32.57 Bn |
| Apr 3, 2022 | 30.39 Bn |
| Jan 2, 2022 | 31.61 Bn |
| Oct 3, 2021 | 31.00 Bn |
| Jul 4, 2021 | 25.31 Bn |